Evidence map›Paper›PMID 37525142›Full record

ArticleBMC cancer2023

Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method.

Purvish Parikh, Govind Babu, Randeep Singh, Vamshi Krishna, Amit Bhatt, Indu Bansal, Senthil Rajappa, Tarini Prasad Sahoo, Shyam Aggarwal, Ajay Bapna and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Purvish ParikhDept of Clinical Hematology, Mahatma Gandhi Medical College Hospital, Jaipur, 302023, India. purvish1@gmail.com.
Govind BabuHCG Cancer Hospital, Bengaluru, 560027, India.
Randeep SinghNarayana Super speciality Hospital, Gurugram, 122002, India.
Vamshi KrishnaAsian Institute of Gastroenterology, Hyderabad, 500082, India.
Amit BhattAvinash Cancer Clinic, Pune, 411004, India.
Indu BansalNarayana Super speciality Hospital, Gurugram, 122002, India.
Senthil RajappaBasavaratakam Indo American Cancer Hospital & Research Institute, Hyderabad, 500034, India.
Tarini Prasad SahooSilverline Hospital, Bhopal, 462001, India.
Shyam AggarwalSir Gangaram Hospital, New Delhi, 110060, India.
Ajay BapnaBhagwan Mahaveer Cancer Hospital and Research Centre, Jaipur, 302017, India.
Ghanshyam BiswasSparsh Hospital & Critical Care, Bhubaneswar, 751007, India.
S P SomashekharManipal Comprehensive Cancer Center, Manipal Hospital, Bengaluru, 560017, India.
Jyoti BajpaiTata Memorial Hospital, Mumbai, 400012, India.
Vashishtha ManiarMumbai Oncocare Center, Mumbai, 400086, India.
Sharad DesaiMahatma Gandhi Cancer Hospital, Miraj, 416410, India.
T RajaApollo Speciality Cancer Hospital, Chennai, 600035, India.
Goura Kishor RathDR. B.R.A. Institute Rotary Cancer Hospital, Delhi, 110029, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrecise prognostication is the key to optimum and effective treatment planning for early-stage hormone receptor (HR) positive, HER2/neu negative breast cancer patients. Differences in the breast cancer incidence and tumor anatomical features at diagnosis, pharmacogenomics data between Western and Indian women along with the vast diversity in the economic status and differences in insurance policies of these regions; suggest recommendations put forward for Western women might not be applicable to Indian/Asian women. Opinions from oncologists through a voting survey on various prognostic factors/tools to be considered for planning adjuvant therapy are consolidated in this report for the benefit of oncologists of the sub-continent, SAARC and Asia's LMIC (low and middle-income countries).

methodsA three-phase DELPHI survey was conducted to collect opinions on prognostic factors considered for planning adjuvant therapy in early-stage HR+/HER2/neu negative breast cancer patients. A panel of 25 oncologists with expertise in breast cancer participated in the survey conducted in 2021. The experts provided opinions as 'agree' or disagree' or 'not sure' in phases-1 and 2 which were conducted virtually; in the final phase-3, all the panel experts met in person and concluded the survey.

resultsOpinions on 41 statements related to prognostic factors/tools and their implications in planning adjuvant endocrine/chemotherapy were collected. All the statements were supported by the latest data from the clinical trials (prospective/retrospective). The statements with opinions of consensus less than 66% were disseminated in phase-2, and later in phase-3 with supporting literature. In phase-3, all the opinions from panelists were consolidated and guidelines were framed.

conclusionsThis consensus guideline will assist oncologists of India, SAARC and LMIC countries in informed clinical decision-making on adjuvant treatment in early HR+/HER2/neu negative breast cancer patients.

Indexed as

Breast NeoplasmsTriple Negative Breast NeoplasmsDeveloping CountriesErb-b2 Receptor Tyrosine KinasesFemaleHumansProspective StudiesRetrospective StudiesSurveys and QuestionnairesErb-b2 Receptor Tyrosine KinasesAvoiding financial distressAvoiding toxicityLow- and middle-income countriesMultigene testsPersonalized therapyPractical recommendationsPrecision oncologyPrognostic testsSaving lives

Identifiers

PMID37525142
PMCPMC10391857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.